Summary

The cell-based assays market is projected to reach USD 24.3 billion by 2029 from an estimated USD 17.3 billion in 2024, at a CAGR of 7.1% during the forecast period from 2024 to 2029. The growth of this market can be attributed to the increasing need of drug discovery and growing demand for cell-based assays in drug discovery. The rising R&D investments by pharmaceutical & biotechnology industries is propelling the growth of cell-based assays market. Also, growing incidences of cancer is promoting the need of advanced therapies resulting to boost the growth of cell-based assays market. Moreover, growing applications of cell-based assays in chronic diseases and personalized medicine is expected to propel the market growth in coming years.
“The drug discovery segment accounted for the largest share of by application segment in 2023.”
Based on application, cell-based assays market is segmented into drug discovery, basic research, genetic studies, and other applications. Drug discovery segment is further categories into toxicity studies, pharmacokinetic studies, and pharmacodynamic studies. In 2023, the drug discovery segment accounted for the largest share of the global cell-based assays market by application. Increasing prevalence of cancer is driving the need of advanced thearpies resulting to promote segment's growth in the cell-based assays market. Additionally, increasing R&D investments, the introduction of new drugs, and the growing number of contract research organizations providing drug discovery services to pharmaceutical and biotechnology companies are also expected to drive to promote the segment's growth in cell-based assays market.
“The flow cytometry segment accounted for the major share by technology segment in 2023.”
Based on technology, cell-based assays market is segmented into flow cytometry, high throughput screening, label free detection, and other technologies. In 2023, the flow cytometry segment accounted for the major share of the global cell-based assays market by technology. The growth of the flow cytometry segment is primarily attributed to the wide usage of flow cytometry for cell-based assays to perform multiple measurements. Additionally, growing adoption of advanced technologies for cell analysis and cell characterization is anticipated to boost the segment growth in cell-based assays market.
“The US has continued to dominate the cell-based assays market in 2023.”
Based on the region, the cell-based assays market is segmented into six major regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, US dominated the cell-based assays market in North America. The US is the world’s largest biopharmaceutical market and a leader in biopharmaceutical research/investments. The US also has a strong healthcare infrastructure, which drives research and development in the life sciences sector. Additionally, the significant presence of many biopharmaceutical companies and growing research activities in the biotechnology industry are propelling market growth in the US. Moreover, growing focus on development of advanced cell-based therapies due to growing incidences of cancer is also driving the growth of the cell-based assays market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 60% and Demand Side 40%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America - 40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
List of Companies Profiled in the Report:

• BD (US)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Lonza (Switzerland)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• Revvity (US)
• Sartorius AG (Germany)
• Corning Incorporated (US)
• Promega Corporation (US)
• Cell Signaling Technology, Inc. (US)
• Eurofins Scientific (Luxembourg)
• Enzo Biochem, Inc. (US)
• Carna Biosciences, Inc. (Japan)
• Intertek Group plc (UK)
• BICO (Sweden)
• Cell Biolabs, Inc. (US)
• Reaction Biology (US)
• AAT Bioquest, Inc. (US)
• Pestka Biomedical Laboratories, Inc. (US)
• Neuromics (US)
• BPS Bioscience, Inc. (US)
• BellBrook Labs (US)
• Profacgen (US)
• BMG LABTECH (Germany)
• Hanugen Theraputics (India)
• Altogen Labs (US)
• BioAgilytix (US)
Research Coverage:
This research report categorizes the cell-based assays market by offering (consumables (reagents, assay kits (reporter gene assays, cell growth assays, second messenger assays, cell death assays, and other assay kits), microplates, cell line (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables), instruments, software, and services, technology (flow cytometry, high throughput screening, label-free detection, and other technologies), application (drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications), end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations and acquisitions, and recent developments associated with the cell-based assays market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, surge in cases of cancer, and increasing R&D investments and fundings for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market
• Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), Revvity (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US) , Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Theraputics (India), Altogen Labs (US), and BioAgilytix (US), among others in the market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 39
1.3.4 CURRENCY CONSIDERED 39
1.4 STAKEHOLDERS 40
1.5 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.1.1 SECONDARY DATA 42
2.1.2 PRIMARY DATA 43
2.2 MARKET ESTIMATION METHODOLOGY 44
2.2.1 BOTTOM-UP APPROACH 44
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 47
2.2.3 TOP-DOWN APPROACH 47
2.3 MARKET GROWTH RATE PROJECTIONS 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 RISK ANALYSIS 51
2.7 LIMITATIONS 51
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 57
4.1 CELL-BASED ASSAYS MARKET OVERVIEW 57
4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2023) 58
4.3 CELL-BASED ASSAYS MARKET, BY OFFERING, 2023 59
4.4 CELL-BASED ASSAYS MARKET, BY END USER, 2023 59
4.5 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
5.2.1 DRIVERS 63
5.2.1.1 Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery 63
5.2.1.2 Government support and funding for cell-based research 64
5.2.1.3 Growing efforts to curtail animal-based studies 65
5.2.1.4 Rising prevalence of cancer 65
5.2.1.5 Alliances to accelerate innovations in drug discovery 67
5.2.2 RESTRAINTS 67
5.2.2.1 High cost of instruments and restrictions imposed by product end-user licenses for reagents 67
5.2.2.2 Lack of standardization of protocols used in cell-based assays 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Growing applications of cell-based assays in chronic diseases and personalized medicine 69
5.2.3.2 Growth opportunities in emerging economies 70
5.2.3.3 Rising adoption of AI in drug discovery and cell analysis 71
5.2.4 CHALLENGES 71
5.2.4.1 Complexities in assay designs 71
5.2.4.2 Shortage of skilled professionals 71
5.3 TECHNOLOGY ANALYSIS 72
5.3.1 KEY TECHNOLOGIES 72
5.3.1.1 Flow Cytometry 72
5.3.1.2 High-throughput screening 73
5.3.1.3 High-content screening 73
5.3.1.4 Label-free detection 73
5.3.2 COMPLEMENTARY TECHNOLOGIES 74
5.3.2.1 Artificial intelligence and machine learning 74
5.3.3 ADJACENT TECHNOLOGIES 74
5.3.3.1 Nanotechnology 74
5.4 SUPPLY CHAIN ANALYSIS 74
5.5 VALUE CHAIN ANALYSIS 76
5.6 PRICING ANALYSIS 77
5.7 ECOSYSTEM ANALYSIS 78
5.7.1 RAW MATERIAL VENDORS 79
5.7.2 PRODUCT/SERVICE VENDORS 79
5.7.3 END USERS 80
5.7.4 REGULATORY BODIES 81
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 81
5.9 PATENT ANALYSIS 82
5.9.1 PATENT METHODOLOGY 82
5.9.2 PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 82
5.9.3 INNOVATION & PATENT APPLICATIONS 83
5.9.4 TOP APPLICANTS 83
5.10 KEY CONFERENCES & EVENTS, 2024–2025 86
5.11 REGULATORY LANDSCAPE 87
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
5.11.2 REGULATORY SCENARIO 91
5.12 PORTER’S FIVE FORCES ANALYSIS 94
5.12.1 THREAT OF NEW ENTRANTS 95
5.12.2 THREAT OF SUBSTITUTES 95
5.12.3 BARGAINING POWER OF SUPPLIERS 95
5.12.4 BARGAINING POWER OF BUYERS 95
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 95
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 96
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 96
5.13.2 BUYING CRITERIA 97
5.14 INVESTMENT & FUNDING SCENARIO 98
5.15 TRADE ANALYSIS 99
5.16 IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET 102
6 CELL-BASED ASSAYS MARKET, BY OFFERING 103
6.1 INTRODUCTION 104
6.2 CONSUMABLES 104
6.2.1 REAGENTS 109
6.2.1.1 High demand for reagents in research applications to propel market growth 109
6.2.2 ASSAY KITS 113
6.2.2.1 Reporter gene assays 117
6.2.2.1.1 Versatility of reporter gene assays and widespread applications to fuel growth 117
6.2.2.2 Cell growth assays 121
6.2.2.2.1 Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market 121
6.2.2.3 Second messenger assays 125
6.2.2.3.1 Adoption of secondary messenger assays for cell signaling studies to fuel growth 125
6.2.2.4 Cell death assays 129
6.2.2.4.1 Importance of cell death quantification in drug development to favor growth 129
6.2.2.5 Other assay kits 132
6.2.3 MICROPLATES 136
6.2.3.1 Demand for microplates in assay development to drive market 136
6.2.4 CELL LINES 139
6.2.4.1 Immortalized cell lines 143
6.2.4.1.1 Wide use of immortalized cell lines to boost market 143
 
6.2.4.2 Primary cell lines 146
6.2.4.2.1 Advantages in drug development, preclinical research, and other applications to propel market 146
6.2.4.3 Stem cell lines 150
6.2.4.3.1 Rising use in tissue and disease models to fuel adoption 150
6.2.5 PROBES & LABELS 154
6.2.5.1 Growing need for effective cell labeling to boost demand 154
6.2.6 OTHER CONSUMABLES 157
6.3 INSTRUMENTS 161
6.3.1 AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH 161
6.4 SERVICES 165
6.4.1 GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH 165
6.5 SOFTWARE 168
6.5.1 INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS TO DRIVE GROWTH 168
7 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY 172
7.1 INTRODUCTION 173
7.2 FLOW CYTOMETRY 173
7.2.1 WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO DRIVE MARKET 173
7.3 HIGH-THROUGHPUT SCREENING 177
7.3.1 INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH 177
7.4 LABEL-FREE DETECTION 180
7.4.1 GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND 180
7.5 OTHER TECHNOLOGIES 184
8 CELL-BASED ASSAYS MARKET, BY APPLICATION 187
8.1 INTRODUCTION 188
8.2 DRUG DISCOVERY 188
8.2.1 TOXICITY STUDIES 192
8.2.1.1 Increasing demand for cell-based assays in toxicity testing to fuel growth 192
8.2.2 PHARMACOKINETIC STUDIES 196
8.2.2.1 Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays 196
8.2.3 PHARMACODYNAMIC STUDIES 200
8.2.3.1 Advantages of cell-based assays in pharmacodynamics to propel growth 200
8.3 BASIC RESEARCH 204
8.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES 204
 
8.4 GENETIC STUDIES 208
8.4.1 INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET 208
8.5 OTHER APPLICATIONS 211
9 CELL-BASED ASSAYS MARKET, BY END USER 215
9.1 INTRODUCTION 216
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 216
9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET 216
9.3 CONTRACT RESEARCH ORGANIZATIONS 221
9.3.1 GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH 221
9.4 ACADEMIC & RESEARCH INSTITUTES 225
9.4.1 RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE MARKET 225
10 CELL-BASED ASSAYS MARKET, BY REGION 229
10.1 INTRODUCTION 230
10.2 NORTH AMERICA 230
10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 231
10.2.2 US 236
10.2.2.1 US to dominate North American cell-based assays market during forecast period 236
10.2.3 CANADA 240
10.2.3.1 Increasing funding and investments to drive market in Canada 240
10.3 EUROPE 243
10.3.1 EUROPE: MACROECONOMIC OUTLOOK 244
10.3.2 GERMANY 248
10.3.2.1 Germany to dominate cell-based assays market in Europe 248
10.3.3 UK 252
10.3.3.1 Growing cancer research funding to increase demand for cell-based assays 252
10.3.4 FRANCE 256
10.3.4.1 Growing biotechnology sector to drive market 256
10.3.5 ITALY 260
10.3.5.1 Growing pharmaceutical industry in Italy to boost market 260
10.3.6 SPAIN 263
10.3.6.1 Rising research activity and increasing number of biotech companies to favor market growth 263
10.3.7 REST OF EUROPE 267
10.4 ASIA PACIFIC 270
10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 271
10.4.2 CHINA 276
10.4.2.1 Increasing R&D expenditure to favor market growth 276
10.4.3 JAPAN 280
10.4.3.1 Government initiatives for drug innovation to support market growth 280
10.4.4 INDIA 283
10.4.4.1 Increasing investments in R&D and funding for life science research to propel market 283
10.4.5 AUSTRALIA 287
10.4.5.1 Booming life science sector to propel market 287
10.4.6 SOUTH KOREA 290
10.4.6.1 Increasing strategic alliances to support market growth 290
10.4.7 REST OF ASIA PACIFIC 294
10.5 LATIN AMERICA 298
10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 299
10.5.2 BRAZIL 303
10.5.2.1 Brazil to hold largest share of Latin American market 303
10.5.3 MEXICO 307
10.5.3.1 Government support for biopharmaceutical production to support market growth 307
10.5.4 REST OF LATIN AMERICA 310
10.6 MIDDLE EAST 314
10.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK 315
10.6.2 GCC COUNTRIES 318
10.6.2.1 Saudi Arabia 322
10.6.2.1.1 Increasing R&D investments to drive market 322
10.6.2.2 UAE 326
10.6.2.2.1 Investments and support for biopharma sector to offer growth opportunities 326
10.6.2.3 Rest of GCC Countries 330
10.6.3 REST OF MIDDLE EAST 333
10.7 AFRICA 337
10.7.1 RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH 337
10.7.2 AFRICA: MACROECONOMIC OUTLOOK 338
11 COMPETITIVE LANDSCAPE 342
11.1 OVERVIEW 342
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 342
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CELL-BASED ASSAYS MARKET 342
11.3 REVENUE ANALYSIS 345
11.4 MARKET SHARE ANALYSIS 346
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 348
11.5.1 STARS 348
11.5.2 EMERGING LEADERS 348
11.5.3 PERVASIVE PLAYERS 348
11.5.4 PARTICIPANTS 348
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 350
11.5.5.1 Company footprint 350
11.5.5.2 Offering footprint 351
11.5.5.3 Technology footprint 352
11.5.5.4 Application Footprint 353
11.5.5.5 Region footprint 354
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 355
11.6.1 PROGRESSIVE COMPANIES 355
11.6.2 RESPONSIVE COMPANIES 355
11.6.3 DYNAMIC COMPANIES 355
11.6.4 STARTING BLOCKS 355
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 357
11.7 VALUATION AND FINANCIAL METRICS 359
11.8 BRAND/PRODUCT COMPARISON 360
11.9 COMPETITIVE SCENARIO 361
11.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 361
11.9.2 DEALS 362
11.9.3 EXPANSIONS 363
12 COMPANY PROFILES 364
12.1 INTRODUCTION 364
12.2 KEY PLAYERS 364
12.2.1 DANAHER CORPORATION 364
12.2.1.1 Business overview 364
12.2.1.2 Products/Services offered 365
12.2.1.3 Recent developments 369
12.2.1.3.1 Deals 369
12.2.1.3.2 Expansions 369
12.2.1.4 MnM view 370
12.2.1.4.1 Key strengths 370
12.2.1.4.2 Strategic choices 370
12.2.1.4.3 Weaknesses & competitive threats 370
12.2.2 THERMO FISHER SCIENTIFIC INC. 371
12.2.2.1 Business overview 371
12.2.2.2 Products/Services offered 373
12.2.2.3 Recent developments 377
12.2.2.3.1 Deals 377
12.2.2.3.2 Expansions 377
12.2.2.4 MnM view 378
12.2.2.4.1 Key strengths 378
12.2.2.4.2 Strategic choices 378
12.2.2.4.3 Weaknesses and competitive threats 378
12.2.3 MERCK KGAA 379
12.2.3.1 Business overview 379
12.2.3.2 Products/Services offered 380
12.2.3.3 Recent developments 383
12.2.3.3.1 Deals 383
12.2.3.3.2 Expansions 384
12.2.3.4 MnM view 384
12.2.3.4.1 Key strengths 384
12.2.3.4.2 Strategic choices 384
12.2.3.4.3 Weaknesses and competitive threats 384
12.2.4 BD 385
12.2.4.1 Business overview 385
12.2.4.2 Products/Services offered 386
12.2.4.3 Recent developments 389
12.2.4.3.1 Product launches 389
12.2.4.3.2 Deals 389
12.2.4.4 MnM view 390
12.2.4.4.1 Key strengths 390
12.2.4.4.2 Strategic choices 390
12.2.4.4.3 Weaknesses and competitive threats 390
12.2.5 AGILENT TECHNOLOGIES, INC. 391
12.2.5.1 Business overview 391
12.2.5.2 Products/Services offered 392
12.2.5.3 Recent developments 393
12.2.5.3.1 Product launches 393
12.2.5.4 MnM view 394
12.2.5.4.1 Key strengths 394
12.2.5.4.2 Strategic choices 394
12.2.5.4.3 Weaknesses & competitive threats 394
12.2.6 LONZA 395
12.2.6.1 Business overview 395
12.2.6.2 Products/Services offered 397
12.2.6.3 Recent developments 398
12.2.6.3.1 Deals 398
12.2.6.3.2 Expansions 398
12.2.7 EUROFINS SCIENTIFIC 399
12.2.7.1 Business overview 399
12.2.7.2 Products/Services offered 400
12.2.7.3 Recent developments 402
12.2.7.3.1 Deals 402
 
12.2.8 CHARLES RIVER LABORATORIES 403
12.2.8.1 Business overview 403
12.2.8.2 Products/services offered 404
12.2.8.3 Recent developments 406
12.2.8.3.1 Service launches 406
12.2.8.3.2 Deals 406
12.2.9 BIO-RAD LABORATORIES, INC. 408
12.2.9.1 Business overview 408
12.2.9.2 Products/Services offered 410
12.2.10 REVVITY 411
12.2.10.1 Business overview 411
12.2.10.2 Products/Services offered 412
12.2.10.3 Recent developments 414
12.2.10.3.1 Product launches 414
12.2.11 SARTORIUS AG 415
12.2.11.1 Business overview 415
12.2.11.2 Products/Services offered 416
12.2.11.3 Recent developments 417
12.2.11.3.1 Expansions 417
12.2.12 CORNING INCORPORATED 418
12.2.12.1 Business overview 418
12.2.12.2 Products/Services offered 419
12.2.13 PROMEGA CORPORATION 420
12.2.13.1 Business overview 420
12.2.13.2 Products/Services offered 420
12.2.14 CELL SIGNALING TECHNOLOGY, INC. 422
12.2.14.1 Business overview 422
12.2.14.2 Products/Services offered 422
12.2.15 ENZO BIOCHEM INC. 424
12.2.15.1 Business overview 424
12.2.15.2 Products/Services offered 425
12.2.15.3 Recent developments 427
12.2.15.3.1 Expansions 427
12.2.16 CARNA BIOSCIENCES, INC. 428
12.2.16.1 Business overview 428
12.2.16.2 Products/Services offered 429
12.2.17 INTERTEK GROUP PLC 431
12.2.17.1 Business overview 431
12.2.17.2 Products/services offered 432
12.2.18 BICO 433
12.2.18.1 Business overview 433
12.2.18.2 Products/Services offered 434
12.3 OTHER PLAYERS 435
12.3.1 CELL BIOLABS, INC. 435
12.3.2 REACTION BIOLOGY 436
12.3.3 AAT BIOQUEST, INC. 437
12.3.4 PESTKA BIOMEDICAL LABORATORIES, INC. 438
12.3.5 NEUROMICS 439
12.3.6 BPS BIOSCIENCE, INC. 439
12.3.7 BELLBROOK LABS 440
12.3.8 PROFACGEN 441
12.3.9 BMG LABTECH 441
12.3.10 HANUGEN THERAPEUTICS 442
12.3.11 ALTOGEN LABS 443
12.3.12 BIOAGILYTIX 444
13 DISCUSSION GUIDE 445
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 450
13.2 CUSTOMIZATION OPTIONS 452
13.3 RELATED REPORTS 452
13.4 AUTHOR DETAILS 453